Viasys gains FDA nod for sleep apnoea therapy:
This article was originally published in Clinica
Viasys Healthcare has gained US FDA 510(k) clearance for its ORION CPAP (continuous positive airway pressure) system for treating patients with obstructive sleep apnoea. The condition affects around 12 million individuals in the US with more than 10 million of these undiagnosed, is due to an abnormal loss of tone in the muscles of the tongue, throat and larynx during sleep, temporarily blocking airflow, said the Conshohocken, Pennsylvania firm. The ORION CPAP system targets a sleep apnoea treatment market that is growing at a rate of 20% per year.
You may also be interested in...
A combined final opinion on the European Chemicals Agency’s proposed microplastic restriction is expected from ECHA committees by year-end, at which point the European Commission will consider whether and when microplastic must be removed from all leave-on cosmetic products marketed in the EU.
Butterfly Network’s CEO Laurent Faracci outlines the company’s growth strategy and plans for their “ultrasound-on-a-chip” technology after its merger with blank check company Longview Acquisition Corp. See what the company’s CEO said about it here.
CDC’s Advisory Committee on Immunization Practices votes 13-1 that these two groups be first in line for vaccination once FDA authorizes a vaccine and ACIP recommends it. Goal of vote is to guide health departments in placing vaccine orders.